Respiratory syncytial virus is the leading cause of hospitalization among U.S. infants. A vaccine, nirsevimab, can reduce the ...

So, which respiratory virus invaded your cells? Several types of viruses could be the culprit: respiratory syncytial virus ...

RSVpreF vaccination is effective against RSV-related lower respiratory tract disease among adults aged 60 years or older.

China pilots monitoring system for pneumonia of unknown origin amid rising respiratory infections, including human ...

Newsweek has created a map showing states where respiratory syncytial virus (RSV) cases are surging.

Zelpultide alfa is under clinical development by Airway Therapeutics and currently in Phase I for Coronavirus Disease 2019 (COVID-19).

Feeling ill after that Christmas or New Year's Eve party? If could be RSV. But how can you know for sure? Here are the ...

Respiratory syncytial virus, or RSV, is a common respiratory virus that infects the nose, throat, and lungs. According to the ...

Vaccine Availability and Accessibility: Vaccines are distributed and administered through a network of healthcare facilities, including public health centers and private clinics. Ensuring ...

Up to now, the company has obtained 17 clinical approvals and carried out 21 clinical trials, among which international cutting-edge technology products such as mRNA respiratory syncytial virus (RSV) ...

Respiratory syncytial virus (RSV) infections can lead to serious complications, particularly in infants and older adults aged ...

Respiratory syncytial virus (RSV) is a major cause of respiratory infections, particularly in infants, children under 5 years, and older adults. Its rapid spread makes RSV a serious public health ...